

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

September 30, 2026

To whom it may concern

Company Name: Daito Pharmaceutical Co., Ltd.
Representative: Hiroshi Matsumori, President and CEO
(Securities Code: 4577, Prime Market of Tokyo Stock Exchange)
Inquiries: Kenji Otsuga, Director, Executive Officer and CFO
(Telephone Number: +81-76-421-5665)

**Execution of JV and Share Transfer Agreement for Transfer of KYORIN
Pharmaceutical's Generic Drug Business to JV by Daito, Meiji Seika Pharma and DBJ**

At the meeting of its board of directors held on September 30, 2026, Daito resolved to establish Pharmatech Co-creation Platform, Inc. jointly with Meiji Seika Pharma and Development Bank of Japan Inc. and to cause Pharmatech Co-creation Platform, Inc. to succeed to the generic drug business of KYORIN Pharmaceutical Co., Ltd.

For details, please refer to the attached press release. The impact of this transaction on Daito's consolidated financial results for the current fiscal year is minor, and there is no revision to the consolidated earnings forecast for the current fiscal year in connection with this transaction. Any impact on Daito's medium- to long-term financial results will be disclosed separately.

End

September 30, 2026

To whom it may concern

Daito Pharmaceutical Co., Ltd.

Meiji Seika Pharma Co., Ltd.

Development Bank of Japan Inc.

Execution of JV and Share Transfer Agreement for Transfer of KYORIN Pharmaceutical's Generic Drug Business to JV by Daito, Meiji Seika Pharma and DBJ

Daito Pharmaceutical Co., Ltd. (hereinafter “Daito”; head office, Toyama City, Toyama; President and CEO Hiroshi Matsumori), Meiji Seika Pharma Co., Ltd. (hereinafter “Meiji Seika Pharma”; head office, Chuo-ku, Tokyo; Representative Director, President Toshiaki Nagasato) and Development Bank of Japan Inc. (hereinafter “DBJ”; head office, Chiyoda-ku, Tokyo; Representative Director, President Hirofumi Maki)—Daito, Meiji Seika Pharma and DBJ, collectively referred to as the “Three Companies”—hereby announce that, following resolutions adopted at the meetings of their respective boards of directors, the Three Companies executed a joint venture agreement (hereinafter the “JV Agreement”) on September 30, 2026 concerning the establishment and operation of Pharmatech Co-creation Platform, Inc. (hereinafter “PCPI”).

On the same date, the Three Companies entered into a share transfer agreement with KYORIN Pharmaceutical Co., Ltd. (hereinafter “KYORIN”; head office, Chiyoda-ku, Tokyo; Representative Director, President and CEO Yutaka Ogihara) (hereinafter the “Share Transfer Agreement,” and the share transfer thereunder, the “Share Transfer”) for the acquisition of all of the issued shares of KYORIN Rimedio Co., Ltd. (hereinafter the “Target Company”; head office, Kanazawa City, Ishikawa; President and Representative Director Hiroshi Hashizume), a consolidated subsidiary of KYORIN engaged in the generic drug business. PCPI is expected to assume the position of purchaser under the Share Transfer Agreement promptly after its establishment.

The establishment of PCPI, the transfer of KYORIN’s generic drug business to PCPI, and the related transactions are collectively referred to in this release as the “Transaction.”

Prior to the Share Transfer, the Target Company plans to implement the following absorption-type company splits (hereinafter the “Pre-Closing Reorganization”). Specifically, the Target Company will succeed to the businesses operated at the Takaoka Plant and the Inami Plant (hereinafter the “Target Plants”) of KYORIN Pharmaceutical Group Facilities Co., Ltd. (hereinafter “KYORIN Pharmaceutical Group Facilities”), a wholly owned subsidiary of KYORIN, while the authorized generic business operated by the Target Company (excluding, however, certain sales-related operations; hereinafter the “AG Business”) will be transferred to KYORIN Pharmaceutical Group Facilities. Accordingly, the business to be succeeded by PCPI through the Transaction will be the business of the Target Company, which includes the businesses relating to the Target Plants and excludes the AG Business (hereinafter the “Target Business”). For details of the structure of the Transaction, please refer to “Structure of the Transaction and Overview of the Target Business” below.

The Transaction is based on the memorandum of understanding announced by Daito on April 24, 2026 in “Execution of a Memorandum of Understanding (MOU) for the Transfer of KYORIN Pharmaceutical Co., Ltd.’s Generic Drug Businesses to a Newly Established Joint Venture by Daito and Two Other Companies,” and the definitive agreements have now been executed following due diligence and discussions among the relevant parties.

Purpose and Details of the JV Agreement and the Share Transfer Agreement

The generic drug industry in Japan has been facing prolonged supply instability triggered by quality-related issues, as well as structural inefficiency stemming from low-volume, high-mix production.

Sharing this recognition of the issues, the joint venture parties have decided to establish PCPI as a platform to promote initiatives that contribute to building a stable supply system for high-quality and affordable pharmaceuticals in the generic drug industry. Under the corporate philosophy “The Power of Co-creation. Reliable Supply. Unwavering Trust.”, PCPI will work to upgrade the stable supply system centered on the

upstream of the value chain (R&D, supply chain, manufacturing and quality assurance), thereby aiming for an early resolution of supply instability for generic drugs and the establishment of a sustainable business foundation.

Under the JV Agreement, PCPI will be operated in an integrated manner with the functions of the joint venture parties, and will primarily promote the following initiatives:

- Promotion of the consolidation of manufacturing sites and the integration of products (including the integration of manufacturing and marketing authorization approvals and product brands), with a view to “moving away from low-volume, high-mix production” and “strengthening stable supply”
- Advancement of the quality control system through the sharing and standardization of quality assurance know-how
- Improvement of R&D efficiency through the integrated operation of portfolio management and development promotion for generic drugs
- Strengthening the resilience of the supply chain through the stable procurement of active pharmaceutical ingredients (APIs) in light of the increasing geopolitical risks
- Enhancement of mutual support for manufacturing infrastructures among the joint venture parties and the Target Plants in light of the increasing risk of natural disasters
- Promoting the utilization of technology and generative AI to maintain a sustainable manufacturing base and quality system

In addition, under the Share Transfer Agreement, PCPI will succeed to the Target Business, which possesses strong R&D capabilities and a robust quality assurance system, the Takaoka Plant which is suited to high-volume production of a limited number of products, and the human capital that supports the stable supply of such generic drugs. In particular, as the Takaoka Plant has substantial available space for the installation of additional equipment and future capacity expansion, it is intended to be developed as a model plant for high-volume production of a limited number of products through the consolidation of manufacturing and the integration of products.

Furthermore, DBJ considers that the Transaction will contribute to improving productivity and quality through the reorganization of the generic drug industry, as well as to strengthening the resilience of Japan’s pharmaceutical supply chain, developing a stable supply system for pharmaceuticals, and enhancing the competitiveness of the pharmaceutical industry clustered in the Hokuriku region. Based on this assessment, DBJ will provide risk capital to PCPI utilizing the “Supply Chain and Infrastructure Fund” (Note 2), a fund under its “Special Investment Operations” (Note 1), and will also support the management of PCPI.

(Note 1) Special Investment Operations, established as an intensive but temporary scheme to supply growth capital from the perspective of promoting the competitiveness of Japanese enterprises along with regional revitalization, draws only a portion of the investment (industrial investment) from the Japanese government—enough to encourage the private sector to supply growth capital.

(Note 2) The “Supply Chain and Infrastructure Fund” is a priority investment area established under the Special Investment Operations to aim at the strengthening the supply chain, through ensuring stable supply of critical products, and fortifying infrastructure, including logistics, through the use of digital technology.

Overview of the Joint Venture Company

(1) Name	Pharmatech Co-creation Platform, Inc. (tentative)
(2) Location	326 Yoka-machi, Toyama City, Toyama (tentative)
(3) Representative’s title and name	Kazumi Tsuji, representative director (tentative)
(4) Businesses	Holding of shares in companies engaged in the manufacture and sale of pharmaceutical products, etc., and management of the business activities of such companies
(5) Share capital	100 million yen (tentative)
(6) Net assets	To be determined.
(7) Total assets	To be determined.
(8) Date of establishment	December 2026 (planned)

(9) Fiscal year end	March (tentative)
(10) Shareholders and ownership ratio	Daito (49.1%), Meiji Seika Pharma (36.0%), DBJ (14.9%)

Notes: A brief biography of Ms. Kazumi Tsuji is set out at the end of this release. As a result of the Transaction, PCPI is expected to become an equity-method affiliate of Daito and Meiji Seika Pharma.

Structure of the Transaction and Overview of the Target Business

The Transaction will be implemented as a series of transactions comprising items 1, and 2. below.

1. Pre-Closing Reorganization (to be implemented at KYORIN)

Details	Effective date
Absorption-type company split whereby the businesses operated by KYORIN Pharmaceutical Group Facilities Co., Ltd. (hereinafter “KYORIN Pharmaceutical Group Facilities”) at the Takaoka Plant and the Inami Plant are transferred to the Target Company	March 31, 2027 (planned)
Absorption-type company split whereby the AG Business operated by the Target Company is transferred to KYORIN Pharmaceutical Group Facilities	March 31, 2027 (planned)

2. Share Transfer

Shares to be transferred	All of the issued shares of the Target Company following the implementation of the Pre-Closing Reorganization (the number of common shares: to be determined; ownership ratio of voting rights, 100.0%)
Transferee	Pharmatech Co-creation Platform, Inc. (PCPI is expected to assume the position of the purchaser promptly after its establishment.)
Transferor	KYORIN Pharmaceutical Co., Ltd.

3. Target Company

(1) Name	KYORIN Rimedio Co., Ltd.
(2) Location	287-1 Moroemachi Shimomachi, Kanazawa City, Ishikawa
(3) Representative’s title and name	Hiroshi Hashizume, president and representative director
(4) Businesses	Manufacture and sale of pharmaceutical products, etc.
(5) Share capital	100 million yen
(6) Date of establishment	October 15, 1947
(7) Major shareholders and ownership ratio	KYORIN Pharmaceutical Co., Ltd. (100.0%)

4. Target Plants

KYORIN Pharmaceutical Group Facilities Co., Ltd. – Takaoka Plant	
(1) Location	8 IC Park, Takaoka City, Toyama
(2) Area	42,457 m ²
(3) Establishment	2024
(4) Number of employees (as of March 2026)	41

KYORIN Pharmaceutical Group Facilities Co., Ltd. – Inami Plant	
(1) Location	885 Inami, Nanto City, Toyama
(2) Area	12,967 m ²
(3) Establishment	1975
(4) Number of employees (as of March 2026)	170

(Reference)

(1) Name	KYORIN Pharmaceutical Group Facilities Co., Ltd.
(2) Location	1-3-7 Otemachi, Chiyoda-ku, Tokyo
(3) Representative's title and name	Kenichi Nakamura, president and representative director
(4) Business	Manufacturing and testing of drugs
(5) Share capital	350 million yen
(6) Date of establishment	October 2, 2017
(7) Major shareholders and ownership ratio	KYORIN Pharmaceutical Co., Ltd. (100.0%)

Expected Timeline

(1) Date of execution of the JV Agreement	September 30, 2026
(2) Date of execution of the Share Transfer Agreement	September 30, 2026
(3) Date of establishment of PCPI	December 2026 (planned)
(4) Effective date of the Pre-Closing Reorganization (absorption-type company splits)	March 31, 2027 (planned)
(5) Effective date of succession (closing date of the Share Transfer)	April 1, 2027 (planned)

End

Inquiries
Daito Pharmaceutical Co., Ltd., Corporate Planning Department TEL: +81-76-421-8755

Company Profiles

About Daito Pharmaceutical Co., Ltd.

Daito (head office, Toyama Prefecture) is a pharmaceutical company that consistently engages in the two pillars of active pharmaceutical ingredients (APIs), which are raw materials for pharmaceuticals, and drug products, from research and development to manufacturing on a global scale. Since its founding in 1942, it has manufactured and sold APIs and drug products for ethical and OTC pharmaceuticals and has a track record of transactions with more than 90% of pharmaceutical companies in Japan. For details, please refer to the website (www.daitonet.co.jp).

About Meiji Seika Pharma Co., Ltd.

Meiji Seika Pharma (head office, Chuo-ku, Tokyo) is the core company responsible for the pharmaceutical business of Meiji Holdings Co., Ltd. Since starting the cultivation of penicillin in 1946, it has been engaged in the research and development, manufacture and sale of ethical pharmaceuticals, including antibacterial drugs, contributing to healthcare in areas such as infectious diseases, the central nervous system and lifestyle-related diseases. In the generic drug business, its strengths lie in high-quality standards and stable supply under the “Meiji” brand. Its group companies include Me Pharma Co., Ltd., a sales company, and Miyako Transportation Co., Ltd., a logistics company. For details, please refer to the website (<https://www.meiji-seika-pharma.co.jp/>).

About Development Bank of Japan Inc.

DBJ (head office, Chiyoda-ku, Tokyo) is a financial institution wholly owned by the Japanese government, established in 2008 under the Development Bank of Japan Inc. Act. Having succeeded to the operations of the former Japan Development Bank (established in 1951) and others, DBJ works to facilitate the smooth supply of funds to customers requiring long-term business funds and to enhance financial functions by providing integrated investment and financing solutions and using other sophisticated financial methods. DBJ has positioned “technological innovation and restructuring of industries” as one of its priority areas and has an extensive track record of investments and loans relating to industrial restructuring and business revitalization. DBJ considers that the Transaction will contribute to improving productivity and quality through the reorganization of the generic drug industry, as well as to strengthening the resilience of Japan’s pharmaceutical supply chain, developing a stable supply system for pharmaceuticals, and enhancing the competitiveness of the pharmaceutical industry clustered in the Hokuriku region. Based on this assessment, DBJ has decided to invest in PCPI through a subscription for class shares, utilizing the “Supply Chain and Infrastructure Fund,” a fund under its “Special Investment Operations.” DBJ will continue to utilize Special Investment Operations to actively support the development of markets for growth capital, the revitalization of the local economy, and the efforts of customers to strengthen their competitiveness. For details, please refer to the website (<https://www.dbj.jp/>).

(Appendix)

Brief Biography of Ms. Kazumi Tsuji, representative director-designate of the Joint Venture company

Apr. 1992 Joined Eli Lilly Japan K.K.

Dec. 2000 Obtained an MBA from the University of San Francisco, U.S.A.

Jan. 2001 Joined Pfizer Japan Inc.

Sep. 2009 Head of Marketing, Established Products Business Unit, Pfizer Japan Inc.

Apr. 2012 Asia Pacific Established Products Lead, Established Products Business Unit, Pfizer Japan Inc.

Jan. 2014 Head of Rheumatology Business Unit, Pfizer Japan Inc.

Aug. 2015 Joined Bristol-Myers Squibb K.K.; Executive Officer, Head of Hepatology and Hematology Business Unit

Jul. 2017 Executive Officer, Head of Innovative Medicines Business Unit, Bristol-Myers Squibb K.K.

Apr. 2019 Executive Officer, Head of Oncology Business Unit, Bristol-Myers Squibb K.K.

Jul. 2021 Appointed Representative Director and President, Mundipharma K.K.

May 2024 Retired as Representative Director and President, Mundipharma K.K.

Nov. 2024 Advisor, Daito Pharmaceutical Co., Ltd., with oversight of the Portfolio Management Department

Oct. 2026 Special Advisor, Daito Pharmaceutical Co., Ltd., (in charge of preparations for the establishment of Pharmatech Co-creation Platform, Inc. and Assistant to Business Development Division (To be appointed))

End